Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Nausea and Vomiting Induced by Motion Sickness - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
The motion sickness market, a crucial segment within the healthcare sector, is set to witness a transformative phase by 2032 according to a detailed market analysis report. This comprehensive research provides in-depth insights into the evolving treatment landscape for nausea and vomiting induced by motion sickness across the major markets, including an epidemiological forecast highlighting the projected growth and emerging trends.
The report delves into a multidisciplinary treatment approach necessary to combat the increased prevalence of motion sickness, especially in industrialized nations where advancements in transportation are more common. Such developments in various modes of transport have contributed to the rise of this condition in the US market, drawing attention to the need for effective therapies.
An examination of over-the-counter (OTC) and generic pharmaceutical offerings reveals that while there are multiple management options currently available—including anticholinergics, antihistamines, and anti-emetics—the market still holds significant potential for new and innovative drugs. One key reason is the partial efficacy and side effects associated with current treatments, highlighting the demand for more effective solutions.
Treating Motion Sickness: A Closer Look at Current and Potential Therapies
- The complexity of the underlying mechanisms of motion sickness-induced nausea and vomiting, which is believed to be due to a disconnect between the visual and vestibular systems in the body.
- Nonpharmacological approaches, such as behavioral and environmental modifications, and the use of herbs, which can provide relief for some individuals.
- A notable market opportunity for companies to invest in research, especially in creating animal models that closely mimic human experiences of nausea and vomiting to support clinical trials.
Furthermore, the scarcity of comprehensive epidemiological data and a lack of uniform guidelines for diagnosis and treatment are challenges that add to the variability and uncertainty in the therapeutic landscape.
Forecasting the Motion Sickness Market through 2032
By analyzing treatment practices, emerging drugs, and market trends, the study provides a holistic view of the state of nausea and vomiting induced by motion sickness treatment. The 2022 market size in the US was the largest among the surveyed markets, with an expectation for continued growth over the next decade. Meanwhile, in the EU and the UK, the market also remains strong, buoyed by standard care treatments that generated substantial revenue.
With thorough segmentation by the mode of transport and detailed country-specific data, the report estimates trends in the 7MM (US, EU4 - Germany, France, Italy, Spain, UK, and Japan) from 2019 to 2032.
Driving Factors and Market Dynamics
The report outlines key drivers of market expansion, including:
- Increased incidence of the condition due to heightened travel and transportation activities
- Opportunities for new therapies prompted by the limited efficacy and side effects of existing treatments
Moreover, emerging therapies like DPI-386 (scopolamine gel) and VLY-686 (tradipitant) hold promising potential to create a positive shift in market trends during the forecast period. These therapies are under close watch as they progress through late-stage clinical trials, hinting at a future where patients have access to rapid-acting and more effective treatment options.
The in-depth report presents a nuanced analysis of the motion sickness-induced nausea and vomiting market outlook. It covers the current and projected 7MM drug outreach, ecosystem players' strategic moves, the anticipated impact of new entrants, market accessibility, reimbursement scenarios, and key opinions from leading healthcare professionals in the field. The insights provided will be instrumental for stakeholders to capture the unfolding market opportunities and navigate the clinical advancements expected in the coming years.
A selection of companies mentioned in this report includes
- Defender Pharmaceuticals
- Vanda Pharmaceuticals
- Eli Lilly
For more information about this report visit https://www.researchandmarkets.com/r/vooru0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
